Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-L1”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06483334
What this trial is testing

Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Who this might be right for
Metastatic Urothelial CarcinomaLocally Advanced Urothelial Carcinoma
Merck Sharp & Dohme LLC 38
Not applicableLooking for participantsNCT07483112
What this trial is testing

Fiber-Boost Randomized Controlled Trial

Who this might be right for
Non-Small Cell Carcinoma of Lung
Cantonal Hospital of St. Gallen 42
Large-scale testing (Phase 3)Study completedNCT02256436
What this trial is testing

Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

Who this might be right for
Urothelial Cancer
Merck Sharp & Dohme LLC 542
Testing effectiveness (Phase 2)Study completedNCT02821754
What this trial is testing

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Who this might be right for
Biliary Tract NeoplasmsLiver CancerHepatocellular Carcinoma+2 more
National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)Study completedNCT03516981
What this trial is testing

Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC 245
Early research (Phase 1)UnknownNCT05780307
What this trial is testing

IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorNon-small Cell Lung CancerSmall Cell Lung Cancer+3 more
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 48
Large-scale testing (Phase 3)Study completedNCT03016312
What this trial is testing

Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Hoffmann-La Roche 759
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Early research (Phase 1)Study completedNCT02827968
What this trial is testing

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumors
3D Medicines (Sichuan) Co., Ltd. 28
Testing effectiveness (Phase 2)UnknownNCT03676946
What this trial is testing

A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma

Who this might be right for
Urothelial Carcinoma
Lee's Pharmaceutical Limited 15
Testing effectiveness (Phase 2)Study completedNCT05661578
What this trial is testing

Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

Who this might be right for
PD-L1-selected Solid Tumors
Hoffmann-La Roche 64
Not applicableUnknownNCT05426317
What this trial is testing

Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression

Who this might be right for
MelanomaNon Small Cell Lung CancerRenal Cancer
University Hospital, Clermont-Ferrand 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT05844150
What this trial is testing

PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Who this might be right for
SCLC
Biotheus Inc. 50
Not applicableUnknownNCT05008796
What this trial is testing

PD-L1 Expression on CTCs in HNSCC Patients Underwent Curative CCRT

Who this might be right for
Head and Neck Squamous Cell CarcinomaCirculating Tumor Cell
Chang Gung Memorial Hospital 50
Testing effectiveness (Phase 2)Looking for participantsNCT07111520
What this trial is testing

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
BioNTech SE 880
Testing effectiveness (Phase 2)Active Not RecruitingNCT04716946
What this trial is testing

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

Who this might be right for
NSCLCNon-small Cell Lung CancerLung Cancer+5 more
Memorial Sloan Kettering Cancer Center 13
Not applicableUnknownNCT04564482
What this trial is testing

PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer

Who this might be right for
Rectal Cancer StageOesophageal Cancer
Johannes Laengle, MD, PhD 20
Testing effectiveness (Phase 2)Study completedNCT05882734
What this trial is testing

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Who this might be right for
Non-Small Cell Lung Cancer
EMD Serono Research & Development Institute, Inc. 61
Large-scale testing (Phase 3)Active Not RecruitingNCT04547504
What this trial is testing

PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %

Who this might be right for
Non-small-cell Lung Cancer
University Hospital, Brest 349
Not applicableLooking for participantsNCT06227728
What this trial is testing

Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.

Who this might be right for
Non Small Cell Lung CancerBreast CancerColorectal Cancer+4 more
Gene Solutions 50
Next Page